var data={"title":"Oxcarbazepine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxcarbazepine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6699?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxcarbazepine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxcarbazepine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxcarbazepine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxcarbazepine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204790\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oxtellar XR;</li>\n      <li>Trileptal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204791\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Trileptal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204825\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204795\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjunctive therapy, partial seizures (epilepsy):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 600 mg daily in 2 divided doses; dose may be increased by as much as 600 mg/day increments at weekly intervals; maximum recommended dose: 1,200 mg/day in 2 divided doses. Although doses &gt;1,200 mg/day were somewhat more efficacious, most patients were unable to tolerate 2,400 mg/day (due to CNS effects).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 600 mg once daily; dosage may be increased by 600 mg/day increments at weekly intervals. Recommended daily dose is 1,200 to 2,400 mg once daily. Although daily doses &gt;1,200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2,400 mg daily (due to CNS effects).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion to monotherapy, partial seizures (epilepsy):</b> Patients receiving concomitant antiepileptic drugs (AEDs): Oral: Immediate release: Initial: 600 mg daily in 2 divided doses while simultaneously reducing the dose of concomitant AEDs. Withdraw concomitant AEDs completely over 3 to 6 weeks, while increasing the oxcarbazepine dose in increments of 600 mg daily at weekly intervals, reaching the maximum oxcarbazepine dose (2,400 mg/day) in about 2 to 4 weeks (lower doses have been effective in patients in whom monotherapy has been initiated).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Initiation of monotherapy, partial seizures (epilepsy):</b> Patients not receiving prior AEDs: Oral: Immediate release: Initial: 600 mg daily in 2 divided doses. Increase dose by 300 mg daily every third day to a dose of 1,200 mg daily. Higher dosages (2,400 mg daily) have been shown to be effective in patients converted to monotherapy from other AEDs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion from immediate release to extended release:</b> Higher doses of extended release formulation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant antiepileptic drugs (AEDs):</b> Concomitant use with enzyme-inducing antiepileptic drugs (eg, carbamazepine, phenobarbital, phenytoin): Extended release: Consider initiating dose at 900 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Neuropathic pain (off-label use):</b> Oral: Initial: 300 mg/day; increase dose after 3 days to 300 mg twice daily, then adjust dose based on response and tolerability in increments of 300 mg every 5 days up to a maximum dose of 900 mg twice daily. Mean dose during clinical trial maintenance period was 1,445 mg/day (Dogra 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204810\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxcarbazepine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxcarbazepine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjunctive treatment, partial seizures (epilepsy):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 2 to 3 years (US labeling): Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 8 to 10 mg/kg/day, not to exceed 600 mg/day, given in 2 divided daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: The target maintenance dose should be achieved over 2 to 4 weeks, and is dependent upon patient weight (should not exceed 60 mg/kg/day given in 2 divided daily doses).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;20 kg: Consider initiating dose at 16 to 20 mg/kg/day; maximum maintenance dose should be achieved over 2 to 4 weeks and should not exceed 60 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 4 to 16 years (US labeling) or 6 to 16 years (Canadian labeling): Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 8 to 10 mg/kg/day, not to exceed 600 mg/day, given in 2 divided daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: The target maintenance dose should be achieved over 2 weeks, and is dependent upon patient weight, according to the following:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 to 29 kg: 900 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">29.1 to 39 kg: 1,200 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;39 kg: 1,800 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children 6 to 17 years: Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 8 to 10 mg/kg once daily (not to exceed 600 mg/day in the first week)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: The target maintenance dose should be achieved over 2 to 3 weeks with dose increases of 8 to 10 mg/kg/day increments at weekly intervals (maximum dosage incremental increase: 600 mg). Target maintenance dose depends on weight:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 to 29 kg: 900 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">29.1 to 39 kg: 1,200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;39 kg: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion to monotherapy, partial seizures (epilepsy):</b> Patients receiving concomitant antiepileptic drugs (AEDs): Children 4 to 16 years (US labeling) or 6 to 16 years (Canadian labeling): Oral: Immediate release: Initial: 8 to 10 mg/kg/day in twice daily divided doses, while simultaneously initiating the dose reduction of concomitant antiepileptic drugs; the concomitant drugs should be withdrawn over 3 to 6 weeks. Oxcarbazepine dose may be increased by a maximum of 10 mg/kg/day at weekly intervals. See below for recommended total daily dose by weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Initiation of monotherapy, partial seizures (epilepsy):</b> Patients not receiving prior AEDs: Children 4 to 16 years (US labeling) or 6 to 16 years (Canadian labeling): Oral: Immediate release: Initial: 8 to 10 mg/kg/day in twice daily divided doses; doses may be titrated by 5 mg/kg/day every third day. See below for recommended total daily dose by weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Range of maintenance doses by weight during monotherapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 kg: 600 to 900 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">25 to 30 kg: 900 to 1,200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">35 to 40 kg: 900 to 1,500 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">45 kg: 1,200 to 1,500 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50 to 55 kg: 1,200 to 1,800 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 65 kg: 1,200 to 2,100 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">70 kg: 1,500 to 2,100 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion from immediate release to extended release:</b> Children &ge;6 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant antiepileptic drugs (AEDs):</b> Children &ge;6 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204796\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: <i>Initial:</i> 300 mg or 450 mg once daily should be considered; dosage may be increased by 300 to 450 mg daily increments at weekly intervals to desired clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204797\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (CrCl &lt;30 mL/minute): Immediate release, Extended release: Therapy should be initiated at one-half the usual starting dose (300 mg daily in adults) and increased slowly to achieve desired clinical response (eg, 300 to 450 mg daily at weekly intervals).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD (on dialysis): Immediate release formulations should be used instead of extended release formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204798\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate impairment: No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; use caution (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: There are no dosage adjustments provided in the manufacturer's labeling; use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204762\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trileptal: 300 mg/5 mL (250 mL) [contains alcohol, usp, methyl hydroxybenzoate, propyl hydroxybenzoate, propylene glycol, saccharin sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trileptal: 150 mg, 300 mg, 600 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg, 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxtellar XR: 150 mg, 300 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204747\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12617171\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Trileptal: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68nh45h+2sg410MW3pb/XP/w==&amp;TOPIC_ID=9467\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Oxtellar XR: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5Wbk3HL/5hJBeW0lK/6jL/Zg==&amp;TOPIC_ID=9467\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204766\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immediate release:</b> Administer twice daily without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Suspension:</i> Prior to using for the first time, firmly insert the plastic adapter provided with the bottle. Cover adapter with child-resistant cap when not in use. Shake bottle for at least 10 seconds, remove child-resistant cap, and insert the oral dosing syringe provided to withdraw appropriate dose. Dose may be taken directly from oral syringe or may be mixed in a small glass of water immediately prior to swallowing. Rinse syringe with warm water after use and allow to dry thoroughly. Discard any unused portion after 7 weeks of first opening bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extended release:</b> Administer once daily on an empty stomach at least 1 hour before or 2 hours after food. Swallow whole; do not cut, crush, or chew the tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133438\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204765\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate-release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">US labeling: Monotherapy or adjunctive therapy in the treatment of partial seizures in adults, as monotherapy in the treatment of partial seizures in children 4 years and older with epilepsy, and as adjunctive therapy in children 2 years and older with partial seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Canadian labeling: Monotherapy or adjunctive therapy in the treatment of partial seizures in patients 6 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extended-release:</i> Adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730958\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Neuropathic pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6224110\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">OXcarbazepine may be confused with carBAMazepine, oxaprozin, oxazepam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Trileptal may be confused with TriLipix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Oxcarbazepine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204754\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. Incidence in children was similar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (20% to 49%), drowsiness (12% to 36%), headache (8% to 32%), ataxia (2% to 31%), abnormal gait (&le;17%), fatigue (3% to 15%), vertigo (2% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (7% to 36%), nausea (15% to 29%), abdominal pain (10% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Diplopia (10% to 40%), nystagmus (3% to 26%), visual disturbance (1% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Lower extremity edema (2%), hypotension (&le;2%), bradycardia, cardiac failure, flushing, hypertension, orthostatic hypotension, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Equilibrium disturbance (7%), nervousness (2% to 5%), amnesia (4%), emotional lability (4%), falling (4%), abnormality in thinking (&le;4%), insomnia (2% to 4%), dysmetria (1% to 3%), speech disorder (1% to 3%), agitation (2%), confusion (2%), lack of concentration (2%), seizure (2%), abnormal electroencephalogram (&le;2%), feeling abnormal (&le;2%), myasthenia (1% to 2%), aggressive behavior, anxiety, apathy, aphasia, aura, cerebral hemorrhage, delirium, delusion, depression, dystonia, euphoria extrapyramidal reaction, hemiplegia, hyperkinesia, hyperreflexia, hypertonia, hypokinesia, hyporeflexia, hypotonia, hysteria, impaired consciousness, intoxicated feeling, malaise, manic behavior, migraine, neuralgia, nightmares, oculogyric crisis, panic disorder, paralysis, personality disorder, precordial pain, psychosis, rigors, seizure (aggravated), stupor, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%), diaphoresis (3%), acne vulgaris (1% to 2%), alopecia, contact dermatitis, eczema, erythematosus rash, facial rash, folliculitis, genital pruritus, maculopapular rash, miliaria, psoriasis, skin photosensitivity, urticaria, vitiligo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum sodium (&lt;135 mEq/L: 7% to 9%), hyponatremia (1% to 3%), weight gain (2%), change in libido, decreased T4, hot flash, hyperglycemia, hypermenorrhea, hypocalcemia, hypoglycemia, hypokalemia, increased gamma-glutamyl transferase, intermenstrual bleeding, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7%), dyspepsia (&le;6%), constipation (4% to 6%), dysgeusia (5%), xerostomia (3%), gastritis (&le;3%), upper abdominal pain (&le;3%), aphthous stomatitis, biliary colic, bloody stools, cholelithiasis, colitis, duodenal ulcer, dysphagia, enteritis, eructation, esophagitis, flatulence, gastric ulcer, gingival hemorrhage, gingival hyperplasia, hematemesis, hemorrhoids, hiccups, increased appetite, retching, sialadenitis, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency (2%), dysuria, hematuria, leukorrhea, priapism, urinary tract pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (2%), purpura, rectal hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (2%), angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (2% to 7%), back pain (4%), muscle spasm (2%), sprain (&le;2%), right hypochondrium pain, systemic lupus erythematosus, tetany</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (4%), accommodation disturbance (&le;2%), blepharoptosis, cataract, conjunctival hemorrhage, hemianopia, mydriasis, ocular edema, photophobia, scotoma, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis externa, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Nephrolithiasis, polyuria, renal pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (5% to 10%), upper respiratory tract infection (7%), pulmonary infection (4%), epistaxis (4%), sinusitis (&le;4%), nasopharyngitis (&le;3%), pneumonia (2%), asthma, dyspnea, laryngismus, pleurisy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthematous pustulosis, agranulocytosis, anaphylaxis, aplastic anemia, atrioventricular block, bone fracture (long-term therapy), decreased bone mineral density (long-term therapy), DRESS syndrome, dysarthria, erythema multiforme, falling, folate deficiency, hepatic failure, hepatitis (Hsu 2010), hypoesthesia, hypothyroidism, increased serum amylase, increased serum lipase, leukopenia, multiorgan hypersensitivity (eosinophilia, arthralgia, rash, fever, lymphadenopathy), osteopenia (long-term therapy), osteoporosis (long-term therapy), pancreatitis, pancytopenia, SIADH, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204769\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxcarbazepine, eslicarbazepine acetate, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for carbamazepine and analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204751\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Agranulocytosis, leukopenia, and pancytopenia have been reported with use (rare); discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone disorders: Long term use has been associated with decreased bone mineral density, osteopenia, osteoporosis, and fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Use has been associated with CNS-related adverse events, most significant of these were cognitive symptoms including psychomotor slowing, difficulty with concentration, and speech or language problems, somnolence or fatigue, and coordination abnormalities, including ataxia and gait disturbances. Caution patients about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Potentially serious, sometimes fatal, dermatologic reactions (eg, Stevens-Johnson, toxic epidermal necrolysis) have been reported in adults and children; the median time to onset was 19 days after treatment initiation. Monitor for signs and symptoms of skin reactions; discontinuation and conversion to alternate therapy may be required. Recurrence of serious skin reactions have been reported with oxcarbazepine rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic dysfunction: Hepatitis has been reported rarely (Hsu 2010). Promptly evaluate any symptoms of hepatic dysfunction (eg, anorexia, nausea/vomiting, right upper quadrant pain, pruritus) and discontinue therapy immediately if significant abnormalities are confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Rare cases of anaphylaxis and angioedema have been reported, even after initial dosing; permanently discontinue should symptoms occur. Use caution in patients with previous hypersensitivity to carbamazepine (cross-sensitivity occurs in 25% to 30% of patients). Potentially serious, sometimes fatal drug reaction with eosinophilia and systemic symptoms (DRESS) also known as multiorgan hypersensitivity reactions have also been reported in close association with initiation of oxcarbazepine; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiovascular, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: Clinically significant hyponatremia (serum sodium &lt;125 mmol/L) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) may develop during use; consider monitoring serum sodium (particularly during the first 3 months of therapy) especially in patients at risk for hyponatremia (eg, elderly patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Hypothyroidism has been reported; consider monitoring thyroid function, particularly in pediatric patients. Discontinuation of therapy has been associated with return of normal thyroxine levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; patients should be instructed to notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Clinical trials excluded patients with significant cardiovascular disease or ECG abnormalities. Monitor body weight/fluid retention in patients with HF; evaluate serum sodium with worsening cardiac function or fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Single-dose studies show that half-life of the primary active metabolite is prolonged 3- to 4-fold and AUC is doubled in patients with CrCl &lt;30 mL/minute; dose adjustment required in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Exacerbation of or new onset primary generalized seizures has been reported, particularly in children. In case of seizure aggravation, discontinue oxcarbazepine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asian ancestry: Consider screening patients of Asian descent for the variant human leukocyte antigen (HLA) allele B*1502 prior to initiating therapy. This genetic variant has been associated with a significantly increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis in patients receiving carbamazepine. Structural similarity of oxcarbazepine to carbamazepine, available clinical evidence, and data from nonclinical studies showing a direct interaction of oxcarbazepine with the HLA-B*1502 protein suggest patients receiving oxcarbazepine may also be at a similar risk. Consider avoiding use of oxcarbazepine in patients with a positive result. Screening is not recommending in low-risk populations or in current oxcarbazepine patients (risk usually during first few months of therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204818\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204756\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9467&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of OXcarbazepine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: OXcarbazepine may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative anticonvulsant with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: OXcarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider an alternative antiepileptic when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: OXcarbazepine may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: OXcarbazepine may decrease the serum concentration of Elvitegravir.  Management: For elvitegravir plus a ritonavir-boosted protease inhibitor, use of oxcarbazepine is not recommended; for elvitegravir/cobicistat/emtricitabine/tenofovir combination products, consider using an alternative antiepileptic when possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May enhance the adverse/toxic effect of OXcarbazepine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): OXcarbazepine may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: OXcarbazepine may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevETIRAcetam: OXcarbazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May increase the serum concentration of OXcarbazepine. OXcarbazepine may decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to oxcarbazepine therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of PHENobarbital. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): OXcarbazepine may decrease the serum concentration of Progestins (Contraceptive).  Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: OXcarbazepine may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selegiline: OXcarbazepine may enhance the serotonergic effect of Selegiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: OXcarbazepine may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: OXcarbazepine may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Alafenamide: OXcarbazepine may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: OXcarbazepine may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May decrease the serum concentration of OXcarbazepine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204758\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204772\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Oxcarbazepine, the active metabolite MHD and the inactive metabolite DHD, crosses the placenta and can be detected in the newborn (Myllynen 2001). According to the manufacturer, data from a limited number of pregnancies collected from pregnancy registries suggest congenital malformations associated with oxcarbazepine monotherapy, including craniofacial defects and cardiac malformations. In general, the risk of teratogenic effects is higher with AED polytherapy than monotherapy (Harden 2009). Plasma concentrations of MHD gradually decrease due to physiologic changes which occur during pregnancy; patients should be monitored during pregnancy and postpartum. Oxcarbazepine may decrease plasma concentrations of hormonal contraceptives.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to oxcarbazepine is ongoing. Patients exposed to oxcarbazepine during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204773\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oxcarbazepine and the active 10-hydroxy metabolite (MHD) are present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204760\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Seizure frequency; serum sodium as deemed necessary (particularly during first 3 months of therapy); symptoms of CNS depression (dizziness, headache, somnolence); hypersensitivity reactions. Additional  serum sodium monitoring recommended during maintenance treatment in patients receiving other medications known to decrease sodium levels, in patients with signs/symptoms of hyponatremia, and in patients with an increase in seizure frequency or severity. Periodic thyroid function tests (particularly pediatric patients) and CBC. Monitor for suicidality (eg, suicidal thoughts, depression, behavioral changes). Serum levels of concomitant antiepileptic drugs during titration as necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27122133\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">The metabolite of oxcarbazepine, 10-monohydroxy metabolite (MHD), is considered the active entity primarily responsible for the therapeutic effects. A number of studies have suggested optimal MHD concentrations for efficacy may range from 2 to 55 mcg/mL and some experts suggest a target range of 8 to 35 mcg/mL based on clinical experience; however, a clear correlation between plasma concentrations and therapeutic response has not been demonstrated. Therapeutic drug monitoring of MHD is not routinely warranted; however, it may be beneficial in optimizing seizure control in the following situations: Extremes of age, during pregnancy, to investigate the correlation between drug concentrations and toxicity especially with concurrent disease states such as renal impairment, to identify potential drug interactions, to assess reasons for therapeutic failure, or to rule out noncompliance (Bring 2008; May 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204750\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pharmacological activity results from both oxcarbazepine and its monohydroxy metabolite (MHD). Precise mechanism of anticonvulsant effect has not been defined. Oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing the propagation of synaptic impulses. These actions are believed to prevent the spread of seizures. Oxcarbazepine and MHD also increase potassium conductance and modulate the activity of high-voltage activated calcium channels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204768\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: MHD: V<sub>d</sub>: 49 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Oxcarbazepine: 67%; MHD: 40%, primarily to albumin; parent drug and metabolite do not bind to alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Oxcarbazepine is extensively metabolized in the liver to its active 10-monohydroxy metabolite (MHD); MHD undergoes further metabolism via glucuronide conjugation; 4% of dose is oxidized to the 10,11-dihydroxy metabolite (DHD) (inactive); 70% of serum concentration appears as MHD, 2% as unchanged oxcarbazepine, and the rest as minor metabolites; <b>Note:</b> Unlike carbamazepine, autoinduction of metabolism has not been observed and biotransformation of oxcarbazepine does not result in an epoxide metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release tablets and suspension have similar bioavailability (based on MDH serum concentrations). Extended release tablets and immediate release products are not bioequivalent. Immediate release: Decreased in children &lt;8 years; increased in elderly &gt;60 years </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (Rey 2004): 2 to 5 years: MHD: Single dose: Mean range: 4.8 to 6.7 hours; 6 to 12 years: MHD: Single dose: Mean range: 7.2 to 9.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: Parent drug: 2 hours; MHD: 9 hours; renal impairment (CrCl 30 mL/minute): MHD: 19 hours; Extended release: Parent drug: 7 to 11 hours; MHD: 9 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 12 years: Immediate release: Oxcarbazepine: 1 hour; MHD: 3 to 4 hours (Rey 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: MHD: Tablets: Median: 4.5 hours (range: 3 to 13 hours); Suspension: Median 6 hours; Extended release: MHD: 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (95%, &lt;1% as unchanged oxcarbazepine, 27% as unchanged MHD, 49% as MHD glucuronides, 3% as DHD (inactive), and 13% as conjugate of oxcarbazepine and MHD); feces (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance (per body weight): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to &lt;4 years: Increased by &sim;80% compared to adults </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 12 years: Increased by &sim;40% compared to adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;13 years: Values approach adult clearance  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204771\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (OXcarbazepine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (250 mL): $273.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Trileptal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (250 mL): $455.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Oxtellar XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $735.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $1,022.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $1,871.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OXcarbazepine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $144.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $263.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $485.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Trileptal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $5.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $9.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (1): $17.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204775\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actinium (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Barzepin (ID);</li>\n      <li>Carbox (BD, LK, PH);</li>\n      <li>Deprectal (MX);</li>\n      <li>Leptal (BD);</li>\n      <li>Lonazet (CO);</li>\n      <li>Neurtrol (TW);</li>\n      <li>Ocnobel (JP);</li>\n      <li>Oksapin (UA);</li>\n      <li>Oleptal (PH);</li>\n      <li>Oxalepsy (PK);</li>\n      <li>Oxalept (HR);</li>\n      <li>Oxazep (BD);</li>\n      <li>Oxcar (PY);</li>\n      <li>Oxetol (BD, LK, MX);</li>\n      <li>Oxpin (KR);</li>\n      <li>Oxrate (IN);</li>\n      <li>Oxypine (TW);</li>\n      <li>Pharozepine (ID);</li>\n      <li>Prolepsi (ID);</li>\n      <li>Sytoclon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Timox (DE);</li>\n      <li>Trexapin (IL);</li>\n      <li>Trileptal (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, HK, HR, ID, IE, IQ, IR, IS, IT, JO, KW, LB, LK, LT, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PR, PY, QA, RO, RU, SA, SE, SI, SK, SY, TH, TR, TW, UY, VE, YE);</li>\n      <li>Trileptin (IL);</li>\n      <li>Tryleptal (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. <i>PM R</i>. 2011;3(4):345-352, 352.e1-e21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/21497321/pubmed\" target=\"_blank\" id=\"21497321\">21497321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. <i>Clin Pharmacokinet</i>. 2008;47(12):767-778. doi: 10.2165/0003088-200847120-00002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19026033/pubmed\" target=\"_blank\" id=\"19026033\">19026033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carrazana E and Mikoshiba I, &ldquo;Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain,&rdquo; <i>J Pain Symptom Manage</i>, 2003, 25(5 Suppl):31-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/12694990/pubmed\" target=\"_blank\" id=\"12694990\">12694990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16139183\"></a>Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. <i>Eur J Pain</i>. 2005;9(5):543&ndash;554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16139183/pubmed\" target=\"_blank\" id=\"16139183\">16139183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17920770\"></a>Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. <i>Pain</i>. 2007;132(3):237-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/17920770/pubmed\" target=\"_blank\" id=\"17920770\">17920770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology.</i> 2009;73(2):133-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu HF, Huang SY. Severe hepatitis associated with administration of oxcarbazepine. <i>Pediatr Int.</i> 2010;52(4):677-678. doi: 10.1111/j.1442-200X.2010.03154.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20958883/pubmed\" target=\"_blank\" id=\"20958883\">20958883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Irving GA, &ldquo;Contemporary Assessment and Management of Neuropathic Pain,&rdquo; <i>Neurology</i>, 2005, 28;64(12 Suppl 3):21-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/15642898/pubmed\" target=\"_blank\" id=\"15642898\">15642898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. <i>Clin Pharmacokinet</i>. 2003;42(12):1023-1042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/12959634/pubmed\" target=\"_blank\" id=\"12959634\">12959634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myllynen P, Pienimaki P, Jouppila P, et al, &ldquo;Transplacental Passage of Oxcarbazepine and its Metabolites <i>in vivo</i>,&rdquo; <i>Epilepsia</i>, 2001, 42(11):1482-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/11879354/pubmed\" target=\"_blank\" id=\"11879354\">11879354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxtellar XR (oxcarbazepine) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rey E, Bulteau C, Motte J, et al, &ldquo;Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy,&rdquo; <i> J Clin Pharmacol</i>, 2004, 44(11):1290-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/15496647/pubmed\" target=\"_blank\" id=\"15496647\">15496647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trileptal (oxcarbazepine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute effective episodes in bipolar disorder. <i>Cochrane Database Syst Rev</i>. 2011;(12):CD004857.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/22161387/pubmed\" target=\"_blank\" id=\"22161387\">22161387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasudev A, Macritchie K, Watson S, Geddes J, Young AH. Oxcarbazepine in the maintenance treatment of bipolar disorder. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD005171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18254071/pubmed\" target=\"_blank\" id=\"18254071\">18254071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23543558\"></a>Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. <i>Cochrane Database Syst Rev</i>. 2013;3:CD007963.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23543558/pubmed\" target=\"_blank\" id=\"23543558\">23543558</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9467 Version 231.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204790\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204791\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204825\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204795\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F204810\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204796\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F204797\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F204798\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204762\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204747\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12617171\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F204766\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133438\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204765\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730958\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6224110\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204754\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204769\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204751\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F204818\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204756\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204758\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204772\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F204773\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F204760\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F27122133\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204750\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204768\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204771\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204775\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9467|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxcarbazepine-patient-drug-information\" class=\"drug drug_patient\">Oxcarbazepine: Patient drug information</a></li><li><a href=\"topic.htm?path=oxcarbazepine-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxcarbazepine: Pediatric drug information</a></li></ul></div></div>","javascript":null}